Amgen to Invest $600 Mn in New R&D Site at Thousand Oaks
The new state-of-the-art facility will be located near Amgen’s headquarters and will house researchers working to accelerate next-generation drug discovery. Construction is scheduled to begin this quarter.
Amgen is investing $600 million to establish a new research and development site in Thousand Oaks, California, a move the company says will create hundreds of U.S. jobs. The announcement was made on September 2.
The new state-of-the-art facility will be located near Amgen’s headquarters and will house researchers working to accelerate next-generation drug discovery. Construction is scheduled to begin this quarter.
The site will be equipped with advanced automation and digital systems aimed at shaping “the next era of scientific discovery,” Amgen CEO Robert Bradway said in the release.
Over the past year, Amgen has announced major domestic investments, including a $900 million expansion of its Ohio manufacturing facility and a $1 billion second manufacturing site in Holly Springs, North Carolina.
The company cited pro-growth tax measures under the Tax Cuts and Jobs Act of 2017, along with the One Big Beautiful Bill Act of 2025, as policy drivers that facilitate further U.S. investment in science and manufacturing.
Amgen’s expansion comes amid broader industry moves to build out U.S. operations as the government implements tariffs on foreign-made medicines. In recent weeks, the United States confirmed a 15 percent tariff on innovative drugs made in the European Union.
Other major pharmaceutical companies, including AstraZeneca, Eli Lilly, Sanofi and Novartis, have also announced large-scale U.S. projects. Last week, Roche revealed plans for a $700 million manufacturing facility in Holly Springs, North Carolina, joining a growing cluster of pharmaceutical companies in the region such as CSL Seqirus, Fujifilm, Johnson & Johnson and Regeneron.
